Federal Court approves Sirtex Medical Limited (ASX:SRX) takeover: Where I would reinvest these funds

The Sirtex Medical Limited (ASX:SRX) share price pushed higher on Wednesday after the Federal Court approved the takeover by CDH Genetech and China Grand Pharmaceutical and Healthcare. What now?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sirtex Medical Limited (ASX: SRX) share price finished the day 1.3% higher at $33.52 this afternoon after the regenerative medicine company provided an update on its takeover approach.

According to the release, the Federal Court of Australia has today made orders approving the scheme of arrangement under which Grand Pharma Sphere, an entity owned by CDH Genetech and China Grand Pharmaceutical and Healthcare Holdings, will acquire all the shares in Sirtex for $33.60 per share.

The next step for Sirtex will be lodging a copy of the Court order with the Australian Securities and Investments Commission tomorrow, after which the scheme will become effective.

Then what happens?

Management expects the company's shares to be suspended from the close of trade on Thursday.

After which, Sirtex shareholders on the share register on the scheme record date (Monday September 17) will be entitled to receive the cash consideration of $33.60 per share. This will then be paid on the implementation date, which is currently expected to be Thursday September 20.

What should you do with the funds?

If you're looking to reinvest these funds back into similar areas of the market then there are two shares that I think are worth considering right now.

Cynata Therapeutics Ltd (ASX: CYP) is a stem cell research company which I think has a bright future ahead of it. Its impressive Cymerus technology can source all of its cells from a single adult donor. Management believes this will increase clinical predictability and cut down on manufacturing costs. It also makes it a more commercially scalable stem cell technology.

Mayne Pharma Group Ltd (ASX: MYX) could be worth considering after the pharmaceutical company advised that the price deflation in the generic drugs market had finally eased. I believe improving market conditions and new product launches put the company in a strong position to return to growth this year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Beach Energy, Meeka Metals, Monash IVF, and Qantas shares are racing higher today

These shares are having a better day than most on Thursday. But why?

Read more »

Female miner in hard hat and safety vest on laptop with mining drill in background.
Broker Notes

Experts reveal 2 buys and 1 sell in the ASX 200 materials sector

And they're not all mining companies, either.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Betmakers, Cettire, Johns Lyng, and Vulcan shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

A smiling miner wearing a high vis vest and yellow hardhat does the thumbs up in front of an open pit copper mine.
Broker Notes

Why Macquarie expects this ASX All Ords copper stock to soar 48% in a year

Macquarie forecasts another big year of gains ahead for this ASX All Ords copper stock. But why?

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

How much upside does Macquarie expect for Steadfast Group shares?

The broker has given its verdict on this blue chip.

Read more »

Female miner standing smiling in a mine.
Broker Notes

Why Macquarie predicts Pilbara Minerals shares could surge 71%

Macquarie forecasts a big rebound ahead for Pilbara Minerals shares. Let’s find out why.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Share Market News

Down 90% from its 2021 peak, can IDP Education shares turn around?

Is this beaten down stock a buy? Let's find out.

Read more »